Skip to main content
NVDA-1.38%AAPL+0.39%GOOGL-2.28%MSFT-0.70%AMZN-0.68%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.31%TSLA-2.02%SKHY+7.05%MU-2.75%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.71%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.36%0005.HK-0.78%HSBA.L-1.48%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.41%AUDJPY-1.70%CHFJPY-1.62%NZDCAD-1.32%EURJPY-1.26%NZDUSD-1.26%GBPJPY-1.25%EURNZD+1.20%USDJPY-1.18%GBPNZD+1.17%CADJPY-1.10%USDZAR+0.84%NZDCHF-0.82%USDNOK+0.79%AUDNZD+0.74%USDSEK+0.70%AUDCAD-0.62%USDTHB+0.61%EURZAR+0.60%EURNOK+0.54%GBPZAR+0.54%AUDUSD-0.51%CADCHF+0.50%USDPLN+0.49%AUDSGD-0.48%USDMXN+0.48%AUDDKK-0.47%EURSEK+0.46%USDCHF+0.46%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%CHFNOK+0.39%EURCHF+0.36%GBPCHF+0.36%GBPHKD+0.32%SGDJPY+0.32%CHFSEK+0.31%NZDSGD-0.29%GBPMXN-0.28%EURHKD-0.26%USDDKK+0.25%USDSGD+0.24%EURPLN+0.24%NOKJPY-0.23%EURCNH-0.17%GBPCAD-0.16%USDILS+0.16%CHFSGD-0.16%EURCAD-0.15%USDTRY+0.11%EURUSD-0.08%GBPSGD-0.07%GBPUSD-0.07%PLNJPY+0.07%AUDCHF-0.07%NZDMXN-0.07%AUDNOK+0.06%USDCAD-0.06%USDCNH+0.06%USDCOP-0.04%EURCZK-0.02%EURGBP+0.02%EURSGD-0.01%USDHKD0.00%EURDKK0.00%GAGUSD-4.64%XAGUSD-4.64%XPTUSD-4.57%HG1-4.04%USOIL+3.43%UKOIL+3.26%COFFEE-2.23%XAUUSD-1.35%GAUUSD-1.34%SUGAR+0.65%XNGUSD-0.57%COTTON+0.32%BTCUSD-1.62%ETHUSD-1.43%USDTUSD-0.03%XRPUSD-2.04%SOLUSD-1.76%TRXUSDT+0.12%ZECUSDT-2.70%DOGEUSD-1.89%XMRUSDT-1.95%LINKUSD-1.00%XLMUSD-1.69%BCHUSDT-4.03%LTCUSD-2.05%UNIUSD-3.20%TONUSD+24.88%HBARUSDT-2.15%SUIUSD-2.13%TAOUSDT-3.31%AAVEUSD-2.63%DOTUSDT-2.36%ICPUSDT-1.44%ONDOUSDT-2.70%WLDUSDT-1.71%ATOMUSDT-2.97%ARBUSDT-0.78%JUPUSDT-3.39%INJUSDT-3.40%STXUSDT-3.80%FETUSDT-3.12%TIAUSDT-1.13%PYTHUSDT-1.61%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-4.03%OPUSDT-1.99%POLUSDT-6.46%IOTAUSDT-4.02%AXSUSDT-2.57%FARTCOINUSDT-4.23%EOSUSDT-0.31%DYDXUSDT-0.53%ORDIUSDT-0.40%GALAUSDT-4.21%NOTUSDT-0.68%RONINUSDT-1.67%NVDA-1.38%AAPL+0.39%GOOGL-2.28%MSFT-0.70%AMZN-0.68%TSM-0.83%SPCX-3.86%AVGO-1.13%META-0.31%TSLA-2.02%SKHY+7.05%MU-2.75%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-2.71%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-2.36%0005.HK-0.78%HSBA.L-1.48%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.41%AUDJPY-1.70%CHFJPY-1.62%NZDCAD-1.32%EURJPY-1.26%NZDUSD-1.26%GBPJPY-1.25%EURNZD+1.20%USDJPY-1.18%GBPNZD+1.17%CADJPY-1.10%USDZAR+0.84%NZDCHF-0.82%USDNOK+0.79%AUDNZD+0.74%USDSEK+0.70%AUDCAD-0.62%USDTHB+0.61%EURZAR+0.60%EURNOK+0.54%GBPZAR+0.54%AUDUSD-0.51%CADCHF+0.50%USDPLN+0.49%AUDSGD-0.48%USDMXN+0.48%AUDDKK-0.47%EURSEK+0.46%USDCHF+0.46%EURAUD+0.45%GBPAUD+0.42%GBPTRY+0.41%CHFNOK+0.39%EURCHF+0.36%GBPCHF+0.36%GBPHKD+0.32%SGDJPY+0.32%CHFSEK+0.31%NZDSGD-0.29%GBPMXN-0.28%EURHKD-0.26%USDDKK+0.25%USDSGD+0.24%EURPLN+0.24%NOKJPY-0.23%EURCNH-0.17%GBPCAD-0.16%USDILS+0.16%CHFSGD-0.16%EURCAD-0.15%USDTRY+0.11%EURUSD-0.08%GBPSGD-0.07%GBPUSD-0.07%PLNJPY+0.07%AUDCHF-0.07%NZDMXN-0.07%AUDNOK+0.06%USDCAD-0.06%USDCNH+0.06%USDCOP-0.04%EURCZK-0.02%EURGBP+0.02%EURSGD-0.01%USDHKD0.00%EURDKK0.00%GAGUSD-4.64%XAGUSD-4.64%XPTUSD-4.57%HG1-4.04%USOIL+3.43%UKOIL+3.26%COFFEE-2.23%XAUUSD-1.35%GAUUSD-1.34%SUGAR+0.65%XNGUSD-0.57%COTTON+0.32%BTCUSD-1.62%ETHUSD-1.43%USDTUSD-0.03%XRPUSD-2.04%SOLUSD-1.76%TRXUSDT+0.12%ZECUSDT-2.70%DOGEUSD-1.89%XMRUSDT-1.95%LINKUSD-1.00%XLMUSD-1.69%BCHUSDT-4.03%LTCUSD-2.05%UNIUSD-3.20%TONUSD+24.88%HBARUSDT-2.15%SUIUSD-2.13%TAOUSDT-3.31%AAVEUSD-2.63%DOTUSDT-2.36%ICPUSDT-1.44%ONDOUSDT-2.70%WLDUSDT-1.71%ATOMUSDT-2.97%ARBUSDT-0.78%JUPUSDT-3.39%INJUSDT-3.40%STXUSDT-3.80%FETUSDT-3.12%TIAUSDT-1.13%PYTHUSDT-1.61%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-3.91%GRTUSDT-4.03%OPUSDT-1.99%POLUSDT-6.46%IOTAUSDT-4.02%AXSUSDT-2.57%FARTCOINUSDT-4.23%EOSUSDT-0.31%DYDXUSDT-0.53%ORDIUSDT-0.40%GALAUSDT-4.21%NOTUSDT-0.68%RONINUSDT-1.67%
ET

Enliven Therapeutics, Inc. (ELVN)

NASDAQ • Healthcare

$57.45
-$1.91 (-3.2%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$59.05
Day Range$57.29 - $59.96
Avg. Volume (3M)847.2K
Market Cap$4.1B
52 Week Range
$14.79$62.32
Next EarningsIn 62 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$105.9M
EPS (TTM)
-$1.64
ROA (TTM)
-11.64%
Current Ratio
64.07

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-14.3%Q1 2026-$0.48
+13.6%Q2 2026-$0.38
-26.6%Q3 2026-$0.49
Next

Nov 11

in 62 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -26.6%

Enliven Therapeutics’ earnings missed expectations in the second fiscal quarter of 2026, with reported August 5, 2026 preliminary results showing EPS of $-0.49 trailed the $-0.39 estimate (-27%) and matched the $-0.49 loss per share a year ago (+0.0% YoY). The company posted a GAAP net loss of roughly $32.5 million, down 28.2% from about $25.3 million a year earlier, alongside a GAAP operating loss of around $37.2 million. Cash burn remained evident, with negative operating cash flow of about $18.5 million for the quarter. For the next period, consensus calls for EPS of $-0.43.

View full earnings history

About Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc. is a NASDAQ-listed Biotechnology company in the healthcare sector that is in the clinical development stage. The company discovers and advances small molecule cancer therapies, giving it the profile of an early-stage drug developer rather than a commercial biopharma business.

Name
Enliven Therapeutics, Inc.
CEO
Richard A. Fair
Website
www.enliventherapeutics.com
Industry
Healthcare
Employees
67

Today's Snapshot

AI-generated

ELVN ended yesterday 3.2% down at 57.45.

Trading Volume

Above 10d avg 929.8K

1.2M

vs S&P 500 Today

Underperforming Market

-2.75%

Updated: September 10, 2026 at 12:15 UTC

Technical Indicators

3 Buy3 Neutral2 Sell
ELVN’s buy classification reflects stronger longer-term moving-average support despite recent short-term softness. The stock is below its 10–20 day averages but comfortably above the 50–200 day averages, and the ADX signals a modest trend while MACD is mildly positive and RSI remains near neutral, indicating limited momentum but room for improvement. Volatility is moderate and money-flow measures are muted, while volume (OBV) is inconsistent, tempering the bullish case. The pivot lies above the current price, marking a near-term resistance. Technical takeaway: Buy — longer-term moving averages provide structural support even amid short-term weakness.
All signals
  • EMA (5 indicators)$39.97 - $58.90
    Buy
  • RSI (14)47.03
    Neutral
  • Stochastic %K (14, 3, 3)42.03
    Neutral
  • MACD Level (12, 26)0.74
    Neutral

Peers & Related Assets

DNTHDianthus Therapeutics, Inc.
$107.04-1.9%
RLAYRelay Therapeutics, Inc.
$18.66-2.4%
PGENPrecigen, Inc.
$6.8-1.0%
SNDXSyndax Pharmaceuticals, Inc.
$19.84-0.5%
INBXInhibrx Biosciences Inc.
$112.86-1.3%
ORICORIC Pharmaceuticals, Inc.
$12.5-0.9%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.